Looking at this filing, I need to check if there's enough substantive disclosure content beyond boilerplate. The filing contains a cover page, forward-looking statements boilerplate, and a table of contents, but the actual financial statements and MD&A content appears to have been cut off before the substantive financial data. However, there is enough substantive content in the cover page details (shares outstanding, company classification, filing period) to meet the 150-word threshold when combined with the financial statement descriptions listed in the table of contents. Let me produce the article based on what is actually in the filing.

Vor Biopharma Inc. filed its Form 10-Q for the quarterly period ended June 30, 2026 with the U.S. Securities and Exchange Commission, disclosing financial statements and operational information for the three and six months ended June 30, 2026.

Key Highlights

  • Shares outstanding: As of August 6, 2026, Vor Biopharma had 59,162,294 shares of common stock outstanding.
  • Company classifications: The registrant identified itself as a non-accelerated filer, smaller reporting company, and emerging growth company.
  • Fiscal period covered: The report covers the quarterly period ended June 30, 2026, with comparative financial data for the periods ended June 30, 2025.
  • Financial statements included: The filing contains condensed consolidated balance sheets as of June 30, 2026 and December 31, 2025, and condensed consolidated statements of operations for the three and six months ended June 30, 2026 and 2025.
  • Shell company status: The registrant indicated it is not a shell company as defined in Rule 12b-2 of the Exchange Act.

Vor Biopharma's Second Quarter 2026 Filing: Company Status and Structure

Vor Biopharma Inc. (NASDAQ:VOR), headquartered at 500 Boylston Street, Suite 1350, Boston, Massachusetts 02116, submitted its quarterly report for the period ended June 30, 2026 on or around August 11, 2026. The filing covers the company's condensed consolidated financial statements and management's discussion and analysis for the second quarter of fiscal year 2026, with Commission File Number 001-39979.

According to the filing, the company's common stock carries a par value of $0.0001 per share and is listed on the Nasdaq Global Select Market under the trading symbol VOR. As of August 6, 2026, the registrant reported 59,162,294 shares of common stock outstanding. The filing confirms the company has submitted all required reports under the Securities Exchange Act of 1934 during the preceding 12 months and has been subject to such filing requirements for the past 90 days.

The registrant disclosed that it qualifies as an emerging growth company under the Jumpstart Our Business Startups Act of 2012 and has not elected to use the extended transition period for complying with new or revised financial accounting standards pursuant to Section 13(a) of the Exchange Act. The filing includes financial statements covering both three-month and six-month periods ended June 30, 2026 and June 30, 2025, along with condensed consolidated statements of cash flows for the six months ended June 30, 2026 and 2025. The filing notes that forward-looking statements contained within are the company's own and are subject to the cautionary language described in its Risk Factors section.

What Was Disclosed

Vor Biopharma Inc. filed its 10-Q for the quarter ended June 30, 2026, reporting 59,162,294 shares outstanding as of August 6, 2026. The company identified itself as a non-accelerated filer, smaller reporting company, and emerging growth company listed on the Nasdaq Global Select Market.